The estimated Net Worth of Gabrielle Alison Silver is at least $441 Tysiąc dollars as of 16 May 2022. Gabrielle Silver owns over 2,500 units of Opiant Pharmaceuticals Inc stock worth over $440,733 and over the last 5 years he sold OPNT stock worth over $0. In addition, he makes $0 as Director at Opiant Pharmaceuticals Inc.
Sign up
Gabrielle Silver OPNT stock SEC Form 4 insiders trading
Gabrielle has made over 6 trades of the Opiant Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 2,500 units of OPNT stock worth $33,225 on 16 May 2022.
The largest trade he's ever made was exercising 14,635 units of Opiant Pharmaceuticals Inc stock on 15 March 2021 worth over $146,350. On average, Gabrielle trades about 2,759 units every 82 days since 2019. As of 16 May 2022 he still owns at least 21,343 units of Opiant Pharmaceuticals Inc stock.
You can see the complete history of Gabrielle Silver stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Gabrielle Silver biography
Dr. Gabrielle Silver is Director of the Company. She has extensive experience managing the growth and profitability of pharmaceuticals and diagnostics businesses with a key focus on neurology. Since October 2015, she has served as a partner at Brunswick Group, an advisory firm specializing in critical issues and corporate relations, where she is co-leading the firm’s global pharmaceutical and healthcare offering. From October 2013 to October 2015, she was an executive at GE Healthcare’s Operating Room Solutions business, a new division at GE Healthcare. From September 2010 to October 2013, she was Global Head of Neuroscience/General Medicine Strategic Marketing at GE. In this role, she developed the disease-focused growth strategy across the diagnostics and imaging portfolio. Earlier in her career, Dr. Silver was the director of the CNS Franchise of Eisai Ltd., UK for which she was responsible for growth and profitability of key brands in the UK including Aricept® and Zonegran®. Prior to her tenure at Eisai, she was Therapeutic Area Director of Neuroscience at Bristol-Myers Squibb UK. Dr. Silver received her Bachelor of Science from the University of Bristol and her Bachelor of Medicine and Bachelor of Surgery from the University of London. She is also a Fellow of the Faculty of Pharmaceutical Medicine in the UK.
How old is Gabrielle Silver?
Gabrielle Silver is 42, he's been the Director of Opiant Pharmaceuticals Inc since 2016. There are 8 older and 1 younger executives at Opiant Pharmaceuticals Inc. The oldest executive at Opiant Pharmaceuticals Inc is Michael Sinclair, 77, who is the Executive Chairman of the Board.
What's Gabrielle Silver's mailing address?
Gabrielle's mailing address filed with the SEC is C/O OPIANT PHARMACEUTICALS, INC., 233 WILSHIRE BLVD, SUITE 400, SANTA MONICA, CA, 90401.
Insiders trading at Opiant Pharmaceuticals Inc
Over the last 21 years, insiders at Opiant Pharmaceuticals Inc have traded over $16,027,532 worth of Opiant Pharmaceuticals Inc stock and bought 199,545 units worth $2,080,156 . The most active insiders traders include Craig A Collard, Marc A Cohen oraz Alain J Cohen. On average, Opiant Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $159,046. The most recent stock trade was executed by Roger Crystal on 27 January 2023, trading 1,358 units of OPNT stock currently worth $27,513.
What does Opiant Pharmaceuticals Inc do?
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.
What does Opiant Pharmaceuticals Inc's logo look like?
Complete history of Gabrielle Silver stock trades at Opiant Pharmaceuticals Inc
Opiant Pharmaceuticals Inc executives and stock owners
Opiant Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Roger Crystal,
President, Chief Executive Officer, Director -
Michael Sinclair,
Executive Chairman of the Board -
Dr. Roger Crystal,
Pres, CEO & Director -
Dr. Phil Skolnick D.Sc. (hon), Ph.D.,
Chief Scientific Officer -
David D. O'Toole,
Chief Financial Officer -
Michael Porter,
IR Contact Officer -
Richard Daly,
Independent Director -
Craig Collard,
Independent Director -
Thomas Thomas,
Director -
Gabrielle Silver,
Director -
Ann MacDougall,
Director -
Aziz Mottiwala,
Chief Commercial Officer -
Rahsaan Thompson,
General Counsel -
Phil Skolnick,
Chief Scientific Officer -
Arvind Agrawal,
Executive Vice President - Medical Affairs -
David O'Toole,
Chief Financial Officer -
Matthew R. Ruth,
Chief Commercial Officer -
Dr. Mark Heath Ellison Ph.D.,
Chief Devel. Officer -
Brian Gorman,
EVP Corp. Devel. & Gen. Counsel -
Ben Atkins,
VP of Communications & Investor Relations -
Matthew R. Ruth,
Chief Commercial Officer -
Ronald W Kaiser,
Director -
Melvin Iii Wesley,
Chief Financial Officer -
William F Stasior,
Director -
Steven G Finn,
Director -
Joseph W Kuhn,
VP & Chief Financial Officer -
Alain J Cohen,
President & Chief Tech Officer -
Marc A Cohen,
Chairman, CEO, Treas, & Sec -
Brian Gorman,
-
Mark Jason Heath Ellison,
Chief Development Officer -
Masuoka K. Lorianne,
Director